TUBB2A Antibody

What is TUBB2A and why is it significant in neurological research?

TUBB2A encodes β2A-tubulin, a critical cytoskeletal protein involved in microtubule formation. Its significance in neurological research stems from its association with cortical and extracortical malformations that lead to cognitive deficits and epilepsy . TUBB2A has also been linked to the formation of tau inclusions, suggesting important roles in neurodegenerative pathways . When designing experiments investigating neurological disorders, researchers should consider TUBB2A's expression patterns across different neural tissues and its interactions with other cytoskeletal components. Comprehensive studies typically require multiple detection methods beyond antibody-based approaches, including gene expression analysis and functional assays to establish causative relationships in disease models.

What experimental applications are TUBB2A antibodies validated for?

TUBB2A antibodies have been validated for multiple experimental applications, with Western Blotting (WB) and Immunoprecipitation (IP) being the most commonly verified . Some antibodies, such as the monoclonal antibody from Boster Bio (catalog #M06868), have been extensively validated across immunohistochemistry applications in multiple tissue types including human colon, liver cancer, stomach cancer tissues, as well as various mouse and rat tissues . For optimal experimental design, researchers should select antibodies with validation in their specific application of interest. The dilution ranges vary significantly by application—for Western blotting, dilutions from 1:50,000 to 1:100,000 have been recommended, while immunoprecipitation typically uses more concentrated solutions at approximately 1:200 .

How should TUBB2A antibodies be stored and handled to maintain optimal activity?

For maintaining optimal antibody activity, TUBB2A antibodies should be stored at -20°C for long-term preservation (up to one year) . For frequent use and short-term storage (up to one month), keeping the antibody at 4°C is recommended . Repeated freeze-thaw cycles should be strictly avoided as they can significantly degrade antibody performance . Most commercial TUBB2A antibodies are supplied in liquid form, often in PBS containing preservatives such as 50% glycerol, 0.5% BSA, and 0.02% sodium azide . These components help maintain stability during storage. When designing experimental timelines, researchers should factor in antibody stability considerations, particularly for longitudinal studies or when comparing results across multiple experimental sessions.

What cross-reactivity considerations should be addressed when using TUBB2A antibodies across multiple species?

TUBB2A antibodies exhibit varying cross-reactivity profiles that researchers must carefully consider when designing comparative studies. Commercial antibodies like Boster's M06868 and Cell Signaling's #51658 demonstrate reactivity to human, mouse, and rat TUBB2A . This cross-reactivity stems from the high conservation of tubulin sequences across mammalian species, but researchers should not assume uniform performance across all species.

When conducting comparative studies, researchers should:

• Validate antibody specificity in each species using positive and negative controls

• Determine optimal working concentrations separately for each species

• Consider potential differences in epitope accessibility due to species-specific post-translational modifications

• Include isotype controls to distinguish specific binding from background

Species-specific optimization is particularly important when quantitative comparisons are being made, as binding affinity may vary even with confirmed cross-reactivity.

What are the recommended validation steps for confirming TUBB2A antibody specificity?

Comprehensive validation of TUBB2A antibody specificity requires a multi-step approach beyond manufacturer testing. Researchers should implement the following validation protocols:

• Western blot analysis to confirm a single band at the expected molecular weight (approximately 55 kDa for TUBB2A)

• Comparison across multiple tissue types with known differential expression patterns

• RNA interference or CRISPR knockout controls to demonstrate signal reduction with target depletion

• Immunoprecipitation coupled with mass spectrometry to confirm target protein identity

• Peptide competition assays using the immunizing peptide to block specific binding

Important considerations include testing for potential cross-reactivity with other β-tubulin isotypes, which share significant sequence homology. Boster Bio's validation approach demonstrates the comprehensive nature of proper antibody validation, including testing across multiple applications (WB, IP, IHC) and using various tissue types for confirmation .

How can researchers optimize immunohistochemistry protocols for TUBB2A detection in different tissue types?

Optimizing immunohistochemistry protocols for TUBB2A requires tissue-specific adjustments to maximize signal-to-noise ratio. Based on validated protocols, researchers should consider:

Critical optimization steps include:

• Testing multiple fixation protocols (paraformaldehyde vs. formalin)

• Comparing different blocking solutions to reduce background

• Adjusting primary antibody incubation time and temperature

• Optimizing detection systems (HRP/DAB vs. fluorescent secondary antibodies)

The extensive validation of the M06868 antibody across multiple human and rodent tissues provides a foundation for these tissue-specific optimizations .

How does TUBB2A expression relate to chemotherapy-induced neurotoxicity mechanisms?

TUBB2A expression levels significantly impact susceptibility to paclitaxel-induced neurotoxicity through several mechanisms. Research has revealed a 63-fold variation in TUBB2A mRNA content across individuals, with important clinical implications . Higher TUBB2A expression confers protection against paclitaxel-induced peripheral neuropathy, as demonstrated in clinical studies where patients carrying certain TUBB2A promoter variants (-101C/-112G) showed a significantly decreased risk of developing paclitaxel neurotoxicity (HR 0.62; 95% CI, 0.42–0.93; P = 0.021) .

The protective mechanism involves:

• Altered microtubule dynamics affecting paclitaxel binding efficiency

• Modified cellular responses to microtubule stabilization

• Reduced susceptibility to paclitaxel-induced apoptosis

In vitro studies using lymphoblastoid cell lines confirmed a statistically significant inverse correlation between TUBB2A gene expression and paclitaxel-induced apoptosis (P = 0.001) . This relationship provides a molecular explanation for differential patient responses to taxane chemotherapy and opens avenues for personalized treatment approaches based on TUBB2A expression profiling.

What is the significance of TUBB2A promoter polymorphisms in predicting chemotherapy outcomes?

TUBB2A promoter polymorphisms represent promising pharmacogenetic markers for predicting chemotherapy outcomes, particularly for taxane-based regimens. Three key polymorphisms have been identified at positions -101, -112, and -157 in the TUBB2A promoter region . The -101 and -112 variants, which exhibit complete linkage disequilibrium, significantly enhance TUBB2A transcription rates .

Clinical significance of these variants includes:

For researchers designing clinical studies, incorporating TUBB2A genotyping can provide valuable stratification data. Methodologically, this requires:

• Targeted sequencing of the TUBB2A promoter region

• Correlation of genotypes with clinical outcomes

• Controlling for treatment schedules, as dosing regimens significantly impact neurotoxicity independent of genetic factors (e.g., weekly 80-90 mg/m² regimens show higher neurotoxicity than 150-175 mg/m² every 21 days, HR 1.91; 95% CI, 1.22–3.00; P = 0.005)

How is TUBB2A emerging as a biomarker for metastatic breast cancer?

TUBB2A has been identified as a novel biomarker candidate for distant metastatic breast cancer through advanced quantitative proteomic analysis of formalin-fixed paraffin-embedded (FFPE) tissues . This identification employed an integrated proteomics approach combining filter-aided sample preparation, tandem mass tag labeling, high pH fractionation, and high-resolution mass spectrometry .

The methodology for establishing TUBB2A as a metastasis biomarker included:

• Comprehensive proteomic profiling identifying over 9,000 proteins from FFPE breast cancer tissues

• Differential expression analysis comparing metastatic vs. non-metastatic samples

• Functional validation through invasion/migration assays

• Real-time PCR confirmation of differential regulation

Researchers investigating breast cancer metastasis should consider incorporating TUBB2A expression analysis in their experimental designs, particularly when examining cytoskeletal remodeling and cellular mobility mechanisms. The biomarker's significance lies in its potential to identify patients at higher risk for distant metastasis, addressing limitations of current biomarkers (HER2, ER, PR) that inadequately differentiate between distant and non-distant metastatic breast cancers .

How can researchers distinguish between different β-tubulin isotypes when investigating specific functions of TUBB2A?

Distinguishing between highly homologous β-tubulin isotypes represents a significant challenge in TUBB2A research. Advanced approaches include:

• Isotype-specific antibody selection: Use antibodies raised against unique peptide sequences, preferably from divergent regions. For TUBB2A, monoclonal antibodies developed against synthetic peptides specific to β2A-tubulin provide higher specificity than those targeting conserved regions .

• Combined immunoprecipitation-mass spectrometry: This approach can confirm antibody specificity and identify the exact tubulin isotype being studied. Immunoprecipitate proteins using the antibody, then perform mass spectrometry to identify unique peptide signatures distinguishing TUBB2A from other isotypes.

• Isotype-specific knockdown/knockout controls: Generate cell lines with reduced expression or complete absence of specific β-tubulin isotypes through RNAi or CRISPR technologies to validate antibody specificity.

• Recombinant protein expression: Express tagged versions of specific tubulin isotypes as standards for antibody validation and identification.

• Correlation with mRNA expression: Combine protein detection with isotype-specific qPCR to confirm that observed protein levels correlate with transcript abundance.

When publishing results, researchers should clearly document the methods used to establish isotype specificity and provide appropriate controls demonstrating the absence of cross-reactivity with other tubulin family members.

What considerations should be taken into account when analyzing contradictory TUBB2A expression data between RNA and protein levels?

When encountering discrepancies between TUBB2A RNA and protein expression data, researchers should implement a systematic analytical approach:

• Temporal dynamics: RNA levels typically change before protein levels. Consider whether sampling time points appropriately capture the relationship between transcription and translation for TUBB2A, which may have specific post-transcriptional regulation.

• Post-transcriptional regulation: Investigate the role of microRNAs targeting TUBB2A mRNA or RNA-binding proteins affecting mRNA stability. The 63-fold variation observed in TUBB2A mRNA content suggests significant regulatory mechanisms beyond transcription .

• Post-translational modifications: Analyze whether antibodies detect all forms of the protein, as modifications may mask epitopes or alter protein stability. TUBB2A undergoes several post-translational modifications that can affect antibody recognition.

• Protein turnover rates: Assess whether differences in protein stability contribute to discrepancies. Microtubule dynamics involve complex protein turnover mechanisms that may not correlate directly with mRNA levels.

• Technical considerations: Evaluate whether differences arise from methodological artifacts:

  • RNA isolation efficiency from different tissues

  • Antibody specificity across applications

  • Detection method sensitivity differences

Researchers should employ multiple detection methods and carefully document the exact epitopes recognized by antibodies to facilitate meaningful comparisons across studies.

What are the most effective strategies for studying TUBB2A in neurodegenerative disease models?

Investigating TUBB2A in neurodegenerative disease contexts requires specialized approaches due to its association with tau inclusions and neuronal function . Effective research strategies include:

• Model system selection: Different models offer complementary insights:

  Model System	Advantages	Applications for TUBB2A Research
  Primary neurons	Physiological relevance, native expression patterns	Cytoskeletal dynamics, axonal transport
  iPSC-derived neurons	Patient-specific mutations, disease modeling	Disease mechanism investigation, personalized drug screening
  Transgenic animals	In vivo pathology progression, behavioral outcomes	Long-term consequences of TUBB2A dysregulation
  Brain organoids	3D architecture, cell-cell interactions	Developmental aspects of TUBB2A function

• Live-cell imaging techniques: Implementing fluorescently tagged TUBB2A constructs with careful validation that tagging doesn't interfere with function.

• Super-resolution microscopy: Techniques like STORM or STED can resolve individual microtubules and potential co-localization with tau aggregates or other disease-relevant structures.

• Tubulin post-translational modification analysis: Investigate how disease states affect TUBB2A-specific modifications using modification-specific antibodies.

• Microtubule dynamics assays: Measure polymerization/depolymerization rates in disease models to determine functional consequences of TUBB2A alterations.

• Axonal transport analysis: Quantify the impact of TUBB2A variants on cargo movement along microtubules, a critical process frequently disrupted in neurodegenerative conditions.

• Drug response profiling: Compare the sensitivity of wild-type versus disease-model neurons to microtubule-targeting drugs to identify therapeutic vulnerabilities or resistances.

These approaches should be combined with careful genetic manipulation strategies that can distinguish TUBB2A-specific effects from general microtubule perturbations.

What emerging research directions are likely to advance our understanding of TUBB2A function?

Several promising research directions are poised to significantly advance our understanding of TUBB2A function in the coming years. These include integrating TUBB2A expression data with patient outcomes to develop predictive biomarkers for both cancer metastasis and chemotherapy responses. The identification of TUBB2A as a potential biomarker for distant metastatic breast cancer highlights its value beyond traditional tubulin functions .

The study of TUBB2A promoter polymorphisms represents another critical research direction, particularly as these genetic variations have demonstrated significant impacts on paclitaxel neurotoxicity risk . Further exploration of the molecular mechanisms underlying this protective effect could lead to new strategies for mitigating chemotherapy side effects.